D-0037-2020 Class I Terminated
FDA drug recall D-0037-2020 was initiated by Shire Human Genetic Therapies, Inc. on Sep 12, 2019 and is designated Class I. Reason for recall: Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing The recall status is terminated (terminated Mar 23, 2021). Affected quantity: 15,075.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 2, 2019
- Initiation Date
- Sep 12, 2019
- Termination Date
- Mar 23, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 15,075
Product description
Natpara (parathyroid hormone) for Injection, 75 mcg, 2 pack medication cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NPS Pharmaceuticals, Inc., Lexington, MA NDC 68875-0204-02
Reason for recall
Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing
Distribution pattern
Product was distributed throughout the United States.
Code information
06628462, exp 5/31/2020 06651000, exp 9/30/2020 06661659, exp 6/30/2020 07110125, 07301073, exp 10/31/2020 07200435, 7/31/2020 07482211, exp 12/31/2020 07630714, exp 3/31/2021 NX170002DA, exp 12/31/2019 NX17004DA, exp 3/31/2020 NX17007DA, NX17007DB, NX17008DA exp 4/30/2020 NX17010DA, NX17012DA, exp 6/30/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0037-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026